Clinical trials: Mask
Thyroid Eye Disease, Graves Ophthalmopathy
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy
- Trial name
- NCT06226545
- Testing
- LASN01
- Where
- 15 sites in United States, Spain and 1 more
- Volunteers
- 41 people
- Sponsor
- Lassen Therapeutics Inc.
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Macular Edema Secondary to Retinal Vein Occlusion
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked.
- Trial name
- QUASAR (NCT05850520)
- Testing
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Fluorescein
- Where
- 273 sites in United States, Australia and 25 more
- Volunteers
- 892 people
- Sponsor
- Bayer
Mydriasis
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
This study evaluated pupil dilation after administration of fixed combination tropicamide-phenylephrine (TR/PH) vs. placebo. Participants attended 3 visits.
- Trial name
- MIST-2 (NCT03751098)
- Testing
- Tropicamide/Phenylephrine ophthalmic solution (TR/PE)
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Eyenovia Inc.
Dry Eye
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
The purpose of this study is to evaluate the efficacy of three different concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of dry eye.
- Trial name
- NCT00926185
- Testing
- Lifitegrast
- Where
- 5 sites in United States
- Volunteers
- 230 people
- Sponsor
- Shire
Dry Age-related Macular Degeneration
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- EXPLORE (NCT04437368)
- Testing
- GT005
- Where
- 55 sites in United States, Australia and 6 more
- Volunteers
- 98 people
- Sponsor
- Gyroscope Therapeutics Limited
Obstructive Sleep Apnea
Evaluation of the F&P Caramel Nasal Mask, US, 2023
The purpose of this clinical investigation is to evaluate the performance and safety of the F\&P Caramel nasal mask in a home environment.
- Trial name
- NCT06060717
- Testing
- F&P Caramel
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fisher and Paykel Healthcare
Obstructive Sleep Apnea
The Evaluation of the Toffee Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea
This investigation is a prospective, non-randomized, non-blinded study. This investigation is designed to evaluate the performance, comfort and ease of use of the F\&P Toffee nasal pillows mask amongst obstructive sleep apnea…
- Trial name
- NCT03242148
- Testing
- Toffee Nasal Pillows Mask
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Fisher and Paykel Healthcare
Presbyopia
A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily
Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations.
- Trial name
- Virgo (NCT04983589)
- Testing
- Pilocarpine HCl, Vehicle
- Where
- 23 sites in United States
- Volunteers
- 230 people
- Sponsor
- Allergan
Non-infectious Anterior Uveitis
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis.
- Trial name
- NCT02406209
- Testing
- NS2, Prednisolone acetate ophthalmic suspension (1%)
- Where
- 15 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Strabismus
Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
Primary objective is to evaluate the efficacy of single-dose treatment with GSK1358820 compared with non-treatment in patients with strabismus based on angles of strabismus in the primary position.
- Trial name
- NCT01584843
- Testing
- GSK1358820
- Where
- 13 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Ocular Hypertension, Open Angle Glaucoma
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
- Trial name
- NCT02874846
- Testing
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye Disease
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734197
- Testing
- SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%
- Where
- 40 sites in United States
- Volunteers
- 349 people
- Sponsor
- Surface Ophthalmics, Inc.
Myopia
CHAMP: Study of NVK-002 in Children With Myopia
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period.
- Trial name
- NCT03350620
- Testing
- NVK-002 Concentration 1, NVK-002 Concentration 2
- Where
- 26 sites in United States, Hungary and 4 more
- Volunteers
- 670 people
- Sponsor
- Vyluma, Inc.
Macular Degeneration
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
The purpose of this study is to compare the safety and effectiveness of bevasiranib given either every 8 weeks or every 12 weeks after an initial pre-treatment with 3 injections of Lucentis® (ranibizumab injection) compared to…
- Trial name
- COBALT (NCT00499590)
- Testing
- bevasiranib, ranibizumab
- Where
- 60 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- OPKO Health, Inc.
Corneal Epithelial Disorders
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02929823
- Testing
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Where
- 19 sites in United States
- Volunteers
- 130 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Acquired Blepharoptosis
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and comfort of RVL-1201 Ophthalmic Solution for an…
- Trial name
- NCT02436759
- Testing
- RVL-1201
- Where
- 14 sites in United States
- Volunteers
- 140 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Ocular Inflammation
Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-303 compared to vehicle and Xibrom™ when dosed for 2 weeks in…
- Trial name
- NCT01190878
- Testing
- ISV-303, DuraSite Vehicle, Xibrom™
- Volunteers
- 169 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Syndromes
A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease
The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.
- Trial name
- NCT01135511
- Testing
- CP-690,550 Eye drops, CP-690,550 Eye drops-vehicle, Sodium Hyaluronate
- Where
- 28 sites in Japan, South Korea
- Volunteers
- 285 people
- Sponsor
- Pfizer
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM…
- Trial name
- NCT04405245
- Testing
- Latanoprost ophthalmic solution, AKB-9778 4%
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.